TP53 and breast neoplasm: The MCF10A and MCF15 HMEC-derived cell lines show large differences in their DNA damage response despite both retaining wild-type p53 [40], and ERα-positive human breast tumours respond poorly to chemotherapy despite having wild-type p53.